296 reports of this reaction
1.5% of all VIGABATRIN reports
#12 most reported adverse reaction
EPILEPSY is the #12 most commonly reported adverse reaction for VIGABATRIN, manufactured by Lundbeck Pharmaceuticals LLC. There are 296 FDA adverse event reports linking VIGABATRIN to EPILEPSY. This represents approximately 1.5% of all 19,478 adverse event reports for this drug.
Patients taking VIGABATRIN who experience epilepsy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EPILEPSY is a less commonly reported adverse event for VIGABATRIN, but still significant enough to appear in the safety profile.
In addition to epilepsy, the following adverse reactions have been reported for VIGABATRIN:
The following drugs have also been linked to epilepsy in FDA adverse event reports:
EPILEPSY has been reported as an adverse event in 296 FDA reports for VIGABATRIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
EPILEPSY accounts for approximately 1.5% of all adverse event reports for VIGABATRIN, making it a notable side effect.
If you experience epilepsy while taking VIGABATRIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.